Thomas J Semrad1,2, Edward J Kim3, I-Yeh Gong3,4, Tianhong Li3, Scott Christensen3, Mili Arora3, Jonathan W Riess3, David R Gandara3, Karen Kelly3. 1. Gene Upshaw Memorial Tahoe Forest Cancer Center, 10121 Pine Avenue, Truckee, CA, USA. tsemrad@tfhd.com. 2. Division of Hematology/Oncology, University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA. tsemrad@tfhd.com. 3. Division of Hematology/Oncology, University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA. 4. Kaiser Permanente, Sacramento, CA, USA.
Abstract
PURPOSE: Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan. METHODS: In this single-center phase 1 study, adult patients with refractory advanced solid tumors received 100 mg/m2 irinotecan intravenously on day 1 and 8 of a 21-day cycle. Alisertib at planned escalating dose levels of 20-60 mg was administered orally twice per day on days 1-3 and 8-10. Patients homozygous for UGT1A1*28 were excluded. The primary objective was the safety of alisertib when combined with irinotecan to determine the maximum tolerated dose (MTD). Secondary objectives included overall response rate by RECIST and pharmacokinetics in a planned expansion cohort of patients with colorectal cancer treated at the MTD. RESULTS: A total of 17 patients enrolled at three dose levels. Dose-limiting toxicities included diarrhea, dehydration, and neutropenia. The MTD of alisertib combined with weekly irinotecan was 20 mg twice per day on days 1-3 and 8-10. One fatal cardiac arrest at the highest dose level tested was deemed possibly related to drug treatment. One partial response in 11 efficacy evaluable patients (9%) occurred in a patient with small cell lung cancer. The study was terminated prior to the planned expansion in patients with colorectal cancer. CONCLUSION: In contrast to prior results in a pediatric population, adult patients did not tolerate alisertib combined with irinotecan at clinically meaningful doses due to hematologic and gastrointestinal toxicities. The study was registered with ClinicalTrials.gov under study number NCT01923337 on Aug 15, 2013.
PURPOSE: Aurora kinases are overexpressed or amplified in numerous malignancies. This study was designed to determine the safety and tolerability of the Aurora A kinase inhibitor alisertib (MLN8237) when combined with weekly irinotecan. METHODS: In this single-center phase 1 study, adult patients with refractory advanced solid tumors received 100 mg/m2 irinotecan intravenously on day 1 and 8 of a 21-day cycle. Alisertib at planned escalating dose levels of 20-60 mg was administered orally twice per day on days 1-3 and 8-10. Patients homozygous for UGT1A1*28 were excluded. The primary objective was the safety of alisertib when combined with irinotecan to determine the maximum tolerated dose (MTD). Secondary objectives included overall response rate by RECIST and pharmacokinetics in a planned expansion cohort of patients with colorectal cancer treated at the MTD. RESULTS: A total of 17 patients enrolled at three dose levels. Dose-limiting toxicities included diarrhea, dehydration, and neutropenia. The MTD of alisertib combined with weekly irinotecan was 20 mg twice per day on days 1-3 and 8-10. One fatal cardiac arrest at the highest dose level tested was deemed possibly related to drug treatment. One partial response in 11 efficacy evaluable patients (9%) occurred in a patient with small cell lung cancer. The study was terminated prior to the planned expansion in patients with colorectal cancer. CONCLUSION: In contrast to prior results in a pediatric population, adult patients did not tolerate alisertib combined with irinotecan at clinically meaningful doses due to hematologic and gastrointestinal toxicities. The study was registered with ClinicalTrials.gov under study number NCT01923337 on Aug 15, 2013.
Entities:
Keywords:
Alisertib; Aurora kinase A; Irinotecan; Phase I
Authors: Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca Journal: Blood Date: 2005-12-22 Impact factor: 22.113
Authors: Laura W Goff; Nilofer S Azad; Stacey Stein; Jennifer G Whisenant; Tatsuki Koyama; Ulka Vaishampayan; Howard Hochster; Roisin Connolly; Amy Weise; Patricia M LoRusso; Safia N Salaria; Wael El-Rifai; Jordan D Berlin Journal: Invest New Drugs Date: 2018-09-06 Impact factor: 3.850
Authors: J R Bischoff; L Anderson; Y Zhu; K Mossie; L Ng; B Souza; B Schryver; P Flanagan; F Clairvoyant; C Ginther; C S Chan; M Novotny; D J Slamon; G D Plowman Journal: EMBO J Date: 1998-06-01 Impact factor: 11.598
Authors: Emma Camacho; Silvia Beà; Itziar Salaverría; Armando López-Guillermo; Xavier Puig; Yolanda Benavente; Silvia de Sanjosé; Elias Campo; Luis Hernández Journal: Int J Cancer Date: 2006-01-15 Impact factor: 7.396
Authors: Müge Sak; Cory T Zumbar; Paul D King; Xiaohui Li; Caroline S Mifsud; Aisulu Usubalieva; Charles D Anderson; Hailey M Chesnick; Joseph P McElroy; Arnab Chakravarti; Eric C Burton; Norman L Lehman Journal: J Neurooncol Date: 2019-04-22 Impact factor: 4.130
Authors: Andres Cervantes; Elena Elez; Desamparados Roda; Jeffrey Ecsedy; Teresa Macarulla; Karthik Venkatakrishnan; Susana Roselló; Jordi Andreu; Jungah Jung; Juan Manuel Sanchis-Garcia; Adelaida Piera; Inma Blasco; Laura Maños; José-Alejandro Pérez-Fidalgo; Howard Fingert; Jose Baselga; Josep Tabernero Journal: Clin Cancer Res Date: 2012-07-02 Impact factor: 12.531
Authors: Gerald Falchook; Robert L Coleman; Andrzej Roszak; Kian Behbakht; Ursula Matulonis; Isabelle Ray-Coquard; Piotr Sawrycki; Linda R Duska; William Tew; Sharad Ghamande; Anne Lesoin; Peter E Schwartz; Joseph Buscema; Michel Fabbro; Alain Lortholary; Barbara Goff; Razelle Kurzrock; Lainie P Martin; Heidi J Gray; Siqing Fu; Emily Sheldon-Waniga; Huamao Mark Lin; Karthik Venkatakrishnan; Xiaofei Zhou; E Jane Leonard; Russell J Schilder Journal: JAMA Oncol Date: 2019-01-10 Impact factor: 31.777
Authors: Todd M Pitts; Erica L Bradshaw-Pierce; Stacey M Bagby; Stephanie L Hyatt; Heather M Selby; Anna Spreafico; John J Tentler; Kelly McPhillips; Peter J Klauck; Anna Capasso; Jennifer R Diamond; S Lindsey Davis; Aik Choon Tan; John J Arcaroli; Alicia Purkey; Wells A Messersmith; Jeffery A Ecsedy; S Gail Eckhardt Journal: Oncotarget Date: 2016-08-02
Authors: Xiaofei Zhou; Shubham Pant; John Nemunaitis; A Craig Lockhart; Gerald Falchook; Todd M Bauer; Manish Patel; John Sarantopoulos; Michael Bargfrede; Andreas Muehler; Lakshmi Rangachari; Bin Zhang; Karthik Venkatakrishnan Journal: Invest New Drugs Date: 2017-08-30 Impact factor: 3.850
Authors: Justin A Chen; Jasmine C Huynh; Chun-Yi Wu; Ai-Ming Yu; Karen Matsukuma; Thomas J Semrad; David R Gandara; Tianhong Li; Jonathan W Riess; Kit Tam; Philip C Mack; Anthony Martinez; Nichole Mahaffey; Karen L Kelly; Edward J Kim Journal: Cancer Chemother Pharmacol Date: 2022-07-30 Impact factor: 3.288